Blog

featured image of AGC Invests $350M+ to Build Mammalian Plant in Japan: Boosting Biopharma Manufacturing

AGC Invests $350M+ to Build Mammalian Plant in Japan: Boosting Biopharma Manufacturing

BIOT

💰 AGC, a Japanese pharmaceutical company, plans to invest over $350 million in a new mammalian cell culture plant in Chiba, Japan. 🏭 This plant will produce cell cultures for biopharmaceutical manufacturing, strengthening AGC's position in the market. 🧪 Construction to be completed by 2022.

featured image of Breakthrough Antibiotic Kills Superbug and Saves Lives

Breakthrough Antibiotic Kills Superbug and Saves Lives

BIOT

🔬 Roche presents resistance-breaking antibiotic! 🦠 Zosurabalpin kills carbapenem-resistant Acinetobacter baumannii by preventing lipopolysaccharide movement. 🧪🐭 MedicalAdvancements

featured image of Revolutionary Cell Transport Tech: No Cryopreservation Needed!

Revolutionary Cell Transport Tech: No Cryopreservation Needed!

BIOT

📰 Likarda, a company spun out of the University of Kansas, revolutionizes cell transportation with Core-Shell Spherification, eliminating cryopreservation. 👩‍🔬🔬👨‍🔬

featured image of Revolutionary Smart Modeling Boosts Bioprocessing Efficiency

Revolutionary Smart Modeling Boosts Bioprocessing Efficiency

BIOT

Scientists and engineers are revolutionizing bioprocessing through smart modeling and analytics software. 🧬🔬💡✅

featured image of Digital Tech Saves Lives: EU Medicines Agency's Innovative Biomanufacturing

Digital Tech Saves Lives: EU Medicines Agency’s Innovative Biomanufacturing

BIOT

🔍 The European Medicines Agency (EMA) emphasizes the role of digital tech in securing drug supplies during emergencies. 🌍🏭👨‍⚕️

featured image of Revolutionary ddPCR: Accurate & Efficient Cell Line Monitoring

Revolutionary ddPCR: Accurate & Efficient Cell Line Monitoring

BIOT

🔬📊 ddPCR: an efficient method for measuring transgene copy numbers and monitoring cell line stability. 💯🧪🔬💡 CellLineStability ddPCR

featured image of BMS Expands Oncology Portfolio with $41bn RayzeBio Acquisition

BMS Expands Oncology Portfolio with $41bn RayzeBio Acquisition

BIOT

💼 Bristol Myers Squibb (BMS) acquires RayzeBio for $4.1bn, expanding its oncology portfolio with targeted radiopharmaceuticals. ⚕️🎯

featured image of Boosting Safety and Sterility in GMP Manufacturing: Aseptic Filling Unveiled!

Boosting Safety and Sterility in GMP Manufacturing: Aseptic Filling Unveiled!

BIOT

🔍 Aseptic Filling: Reducing Risk and Improving Sterility in GMP Manufacturing explores the importance of proper training and cleanroom design to ensure product safety. 💉🧪

featured image of Bioprocessing Revolution: $44 Billion Industry by 2030

Bioprocessing Revolution: $44 Billion Industry by 2030

BIOT

💡 The bioprocessing market is booming, 💊 driven by biotechnology advancements and rising demand for biopharmaceuticals. 🌍🏭🌱

featured image of Nobel Prize Winner Credits Bayh-Dole Act for Medical Breakthroughs

Nobel Prize Winner Credits Bayh-Dole Act for Medical Breakthroughs

BIOT

🔍 The Bayh-Dole Act nurtures medical innovation by allowing universities to own federally funded research. Nobel laureate Katalin Karikó explains. 💡🧪🔬💉🚀🌍